Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
OptimizeRx ( (OPRX) ) just unveiled an update.
OptimizeRx announced the resignation of William J. Febbo from his roles as CEO and Board Member effective December 31, 2024, and outlined the terms of his separation agreement. The agreement includes a continuation of salary, bonus payment, and health benefits for Febbo, who will also provide advisory services until March 2025, while adhering to non-compete and non-solicitation clauses, reflecting a structured leadership transition with potential implications for company stability and stakeholder relations.
More about OptimizeRx
OptimizeRx operates in the healthcare technology industry, providing digital health solutions that facilitate communication between healthcare stakeholders, including pharmaceutical companies, healthcare providers, and patients, with a focus on improving patient care outcomes.
YTD Price Performance: 3.84%
Average Trading Volume: 304,871
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $99.66M
For an in-depth examination of OPRX stock, go to TipRanks’ Stock Analysis page.
